Anti-B7H3 nanobody (Bao Pharmaceuticals)

抗B7-H3纳米抗体 (宝济药业)

Report date: 2026/05/15 20:01:45

Base Information

Drug NameAnti-B7H3 nanobody (Bao Pharmaceuticals)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionAnti-CD276

TargetsCD276 antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesShanghai Bao Pharmaceuticals Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Bao Pharmaceuticals Co Ltd

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A